Tesamorelin is a synthetic analog of growth-hormone-releasing hormone (GHRH). Rather than replacing growth hormone directly, it stimulates the pituitary to release the body’s own — a more physiological approach that has carried it all the way to regulatory approval.
What you’re reading about
Tesamorelin (developed as TH9507) is FDA-approved for a specific condition — excess visceral abdominal fat in HIV-associated lipodystrophy — making it one of the few peptides in this library to have completed the full path to approval.
Mechanism
As a GHRH analog, tesamorelin binds pituitary GHRH receptors and prompts pulsatile release of endogenous growth hormone, raising GH and IGF-1 within the body’s own regulatory rhythm.
Research applications
- Visceral fat and metabolic research.
- The GHRH–GH–IGF-1 axis.
- Cognitive and body-composition endpoints.
Clinical outlook
Tesamorelin’s clinical record is substantial. Its pivotal Phase 3 program established efficacy and safety in HIV-associated lipodystrophy (NCT00608023), leading to approval, and further trials have explored metabolic endpoints such as type 2 diabetes (NCT01264497). Researchers continue to investigate GHRH-analog approaches to visceral fat and metabolic health.
